Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was rated a ‘Buy’ with a price target of $61, indicating a 354.21% potential upside. The company is focused on developing psychedelic agents for mental health disorders, with strong clinical data expected. Analysts are bullish on MNMD, with a consensus ‘Buy’ rating and a median price target of $24.50.

Rio Tinto’s CEO plans to generate up to $10 billion through divestments and other strategies. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) faces clinical and regulatory risks due to its lead candidate’s relation to LSD but could see regulatory approval with robust Phase III data. Analysts reaffirm a ‘Buy’ rating with a price target of $55, offering a 310% upside potential.

Read more at Yahoo Finance: What’s Driving JonesTrading’s Bullish View on Mind Medicine (MindMed) Inc. (MNMD)